Drug approved to treat high blood pressure

(HealthDay) -- The high blood pressure drug Toprol XL has been combined with a low-dose diuretic to form Dutoprol (metoprolol succinate extended release/hyrdrochlorothiazide), which has been approved by the U.S. Food and Drug Administration to treat high blood pressure.

Toprol XL has been approved in the United States for 20 years as a treatment for hypertension, British drugmaker AstraZeneca said in a news release.

The drug maker said it will charge $18.33 per month when a 90-day supply of the combination drug is ordered with a valid prescription, whether or not the patient has insurance. Retail drug stores also will stock the combination medication.

AstraZeneca said the drug may not be recommended for people with a significantly slow heart rate, uncontrolled heart failure, or allergies to the drug's ingredients.

More information: Medline Plus has more information about Dutoprol's active ingredient.

add to favorites email to friend print save as pdf

Related Stories

FDA approves a new beta blocker

Dec 18, 2007

The U.S. Food and Drug Administration has approved Bystolic, a beta blocker, for the treatment of high blood pressure. Bystolic (nebivolol) is a new drug not previously approved for use in the United States.

Two pancreatic-enzyme products approved

Mar 02, 2012

(HealthDay) -- Two drugs that supplement the digestion-aiding actions of pancreatic enzymes have been approved by the U.S. Food and Drug Administration, the agency said Thursday in a news release.

FDA approves skin cancer drug

Oct 13, 2006

The U.S. Food and Drug Administration approved a new drug to treat a rare, slow-growing skin cancer.

Recommended for you

Generic form of nexium approved

6 hours ago

(HealthDay)—The first generic version of the heartburn drug Nexium (esomeprazole) has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.